Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Actelion Ltd (ATLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Actelion Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.
Actelion Ltd Key Recent Developments
May 22,2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
May 15,2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
Feb 14,2017: Actelion announces excellent financial results for 2016
Nov 07,2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond
Oct 20,2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Actelion Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include endothelin receptor antagonists (ERAs) Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty products include Valchlor (mechlorethamine), Ledaga (chlormethine) and Zavesca (miglustat). Actelion also offers approved treatments for diseases such as Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients with systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. The company offers its products in various countries across Europe, besides Japan, China, Russia, Mexico and the US. Actelion is headquartered in Allschwil, Switzerland.
Actelion Ltd Key Recent Developments
May 22,2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
May 15,2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
Feb 14,2017: Actelion announces excellent financial results for 2016
Nov 07,2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond
Oct 20,2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
Section 1 - About the Company 5
Actelion Ltd - Key Facts 5
Actelion Ltd - Key Employees 6
Actelion Ltd - Key Employee Biographies 7
Actelion Ltd - Major Products and Services 9
Actelion Ltd - History 10
Actelion Ltd - Company Statement 13
Actelion Ltd - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Joint Venture 17
Section 2 Company Analysis 18
Actelion Ltd - Business Description 18
Actelion Ltd - SWOT Analysis 19
SWOT Analysis - Overview 19
Actelion Ltd - Strengths 19
Actelion Ltd - Weaknesses 20
Actelion Ltd - Opportunities 21
Actelion Ltd - Threats 22
Actelion Ltd - Key Competitors 23
Section 3 Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios - Ratio Charts 29
Section 4 Companys Lifesciences Financial Deals and Alliances 30
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Actelion Ltd, Recent Deals Summary 32
Section 5 Companys Recent Developments 33
May 22, 2017: Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia 33
May 15, 2017: Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson 35
Feb 14, 2017: Actelion announces excellent financial results for 2016 36
Nov 07, 2016: Actelion To Provide An Update On Advancements In Its Cardiovascular Pipeline In PAH And Beyond 40
Oct 20, 2016: Excellent Operational Results - Supported By Outstanding Uptravi Launch - Financial Guidance Upgraded 42
Jul 21, 2016: Very Strong Performance in the First Half Of 2016 - Enhanced by Successful Uptravi US Launch 45
Apr 21, 2016: Very Strong Performance Continues In The First Quarter Of 2016 - Driven By Outcome-Based Pah Portfolio 49
Section 6 Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56
List Of Tables
Actelion Ltd, Key Facts 5
Actelion Ltd, Key Employees 6
Actelion Ltd, Key Employee Biographies 7
Actelion Ltd, Major Products and Services 9
Actelion Ltd, History 10
Actelion Ltd, Subsidiaries 14
Actelion Ltd, Joint Venture 17
Actelion Ltd, Key Competitors 23
Actelion Ltd, Ratios based on current share price 24
Actelion Ltd, Annual Ratios 25
Actelion Ltd, Annual Ratios (Cont...1) 26
Actelion Ltd, Annual Ratios (Cont...2) 27
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Actelion Ltd, Recent Deals Summary 32
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55
List Of Figures
Actelion Ltd, Performance Chart (2012 - 2016) 28
Actelion Ltd, Ratio Charts 29
Actelion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Actelion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 31
RELATED REPORTS
Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report
Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance ReportActelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report
View ReportAntidiarrhoeals Drugs Global Market Report 2020 Including: 1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs 2) By Application: Adults, Childrens 3) By Type: OTC drugs, Prescription Drugs Covering: GlaxoSmithKline, Actelion, Perrigo, Lupin, Glenmark Pharmaceuticals
Antidiarrhoeals Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global antidiarrhoeals drugs market.Reasons
View ReportActelion Pharmaceuticals Ltd (ATLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Actelion Pharmaceuticals Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development
View ReportActelion Ltd (ATLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
Actelion Ltd (Actelion) is a biopharmaceutical company, which strives to discover, develop and commercialize innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
